Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Journal of Assisted Reproduction and Genetics
Erschienen in: Journal of Assisted Reproduction and Genetics 2-3/2007

01.03.2007 | Original Paper

Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: A meta-analysis

verfasst von: João Batista A. Oliveira, Ana Lucia Mauri, Claudia G. Petersen, Anice M. C. Martins, João Cornicelli, Mario Cavanha, Anagloria Pontes, Ricardo L. R. Baruffi, José G. Franco Jr

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 2-3/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose: to compare the efficacy of recombinant LH supplementation for controlled ovarian stimulation in recombinant FSH and GnRH-agonist protocol.
Methods: Search strategies included on-line surveys of databases. The fixed effects model was used for odds ratio and effect size (weighted mean difference). Four trials fulfilled the inclusion criteria.
Results: a fewer days of stimulation (p<0.0001), a fewer total amount of r-FSH administered (p<0.0001) and a higher serum estradiol levels on the day of hCG administration (p<0.0001) were observed for the r-LH supplementation protocol. However, differences were not observed in number of oocyte retrieved, number of mature oocytes, clinical pregnancy per oocyte retrieval, implantation and miscarriage rates.
Conclusions: more randomized controlled trials are necessary before evidence-based recommendations regarding exogenous LH supplementation in ovarian stimulation protocols with FSH and GnRH-agonist for assisted reproduction treatment can be provided.
Literatur
1.
Sills EA, Levy DP, Moomjy M, McGee M, Rosenwaks Z. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulation hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum Reprod 1999;14:2230–5PubMedCrossRef
2.
Humaidan P, Bungum M, Bungum L, Andersen YC. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004;8:635–43PubMed
3.
Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001;179:39–46PubMedCrossRef
4.
Zeleznik AJ. Follicle selection in primates: “Many are called but few are chosen.” Biol Reprod 2001;65:655–9PubMedCrossRef
5.
Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenese. Hum Reprod 1994;9:188–91PubMed
6.
Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002;77: 1170–7PubMedCrossRef
7.
Mulrow CD, Oxman AD. Cochrane Collaboration Handbook, Oxford: Cochrane Collaboration 1996
8.
Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002;5:104–8PubMedCrossRef
9.
Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (folitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2003;8:175–82
10.
Tarlatzis B, Tavmergen E, Szamatowicz M, Amit A, Levitas E, Shoham Z. The use of recombinat human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006;21:90–4PubMedCrossRef
11.
Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206–12PubMed
12.
Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003–8PubMedCrossRef
13.
O’Dea L, St L, The US Recombinant Study Group. Recombinant LH in support of recombinant FSH in female hypogonadotropic hypogonadism—Evidence of threshold effects (abstract). Fertil Steril 2000;74 (suppl.3):S36CrossRef
14.
De Placido G, Alviggi C, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A, Colacurci N, Tolino A, Wilding M. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod 2001;16:1875–9PubMedCrossRef
15.
Fbregues F, Balasch J, Creus M, Civico S, Carmona F, Puerto B, Vanrell JA. Long-term down-regulation does not improve pregnancy rates in an in vitro fertilization program. Fertil Steril 1998;70:46–51CrossRef
16.
Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryos function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13:1788–92PubMedCrossRef
17.
Davis OK, Rosenwaks Z. Currents status of in vitro fertilization and new reproductive technologies. Curr Opin Obstet Gyneco 1992;4:354–8
18.
19.
20.
Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod 2002;17:3129–37PubMedCrossRef
21.
De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, Wilding M, Varricchio MT, Borrelli AL, Conforti S. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol 2004;60: 637–43CrossRef
22.
Balasch J, Peñarrubia J, Fábregues F, Vidal E, Casamitjana R, Manau D, Carmona F, Creus M, Vanrell JA. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reprod Biomed Online 2003;7:35–42PubMed
23.
Humaidan P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Letter to editor. Hum Reprod Update 2006;12:325–6PubMedCrossRef
24.
Kolibianakis EM, J Collins J, Tarlatzis JB, Papanikolaou E, Devroey P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum Reprod Update 2006;12:03–12CrossRef
25.
Balasch J, Fábregues F. LH in the follicular phase: neither too high nor too low. Reprod Biomed Online 2006;12:406–15PubMed
Metadaten
Titel
Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: A meta-analysis
verfasst von
João Batista A. Oliveira
Ana Lucia Mauri
Claudia G. Petersen
Anice M. C. Martins
João Cornicelli
Mario Cavanha
Anagloria Pontes
Ricardo L. R. Baruffi
José G. Franco Jr
Publikationsdatum
01.03.2007
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 2-3/2007
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-006-9095-4

Weitere Artikel der Ausgabe 2-3/2007

Journal of Assisted Reproduction and Genetics 2-3/2007 Zur Ausgabe

Original Paper

Intrauterine insemination in natural cycle may give better results in older women

Physiology

Effect of apoptosis and reactive oxygen species production in human granulosa cells on oocyte fertilization and blastocyst development

Brief Communication

Light exposure of the ovum and preimplantation embryo during ART procedures

The JARG Blog

The JARG Blog1

Assisted Reproduction

In vitro tagging of embryos with nanoparticles

Assisted Reproduction

The pre-cycle blind mock embryo transfer is an inaccurate predictor of anticipated embryo transfer depth

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise